EV
Dr. Elena Vasquez
Chief Executive Officer
A cell-therapy process scientist turned operator, Elena founded Solua after two decades shepherding living medicines from bench to commercial supply. She keeps the company anchored to a single question: will this reach the patient?
MO
Dr. Marcus Okonkwo
Chief Scientific Officer
Marcus leads Solua's science across cell, vector and EV modalities. A pioneer of closed-system processing, he architected the Coherra™ platform around the conviction that consistency is engineered, not hoped for.
PR
Priya Ramachandran
Chief Operating Officer
Priya runs Solua's three GMP facilities and the network that connects them. Her focus is reliable, scalable operations — turning brilliant processes into batches that ship on time, every time.
JH
Dr. James Hartley
VP, Quality & Compliance
James owns the harmonized quality system that spans development to commercial. A veteran of more than a dozen regulatory inspections, he treats inspection readiness as a daily discipline rather than a fire drill.
YT
Dr. Yuki Tanaka
VP, Analytical & Bioassay Sciences
Yuki builds the assays that decide what can be released. Her teams specialize in mechanism-relevant potency methods for therapies that defy conventional measurement, from iPSC-derived cells to engineered vesicles.
DC
David Chen
VP, Regulatory Affairs & CMC
David translates process and analytical science into defensible regulatory strategy. He has guided programs through pre-licensing inspections and first commercial approvals across multiple jurisdictions.
AK
Dr. Amara Keita
VP, Business Development & Partnerships
Amara is the first scientist most partners meet. With a research background in viral vectors, she scopes programs honestly — matching ambition to what the biology and the timeline can actually support.